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STUDY QUESTION: How did coronavirus disease 2019 (COVID-19) impact on medically assisted reproduction (MAR) services in
Europe during the COVID-19 pandemic (March to May 2020)?
SUMMARY ANSWER: MAR services, and hence treatments for infertile couples, were stopped in most European countries for a mean
of 7 weeks.
WHAT IS KNOWN ALREADY:With the outbreak of COVID-19 in Europe, non-urgent medical care was reduced by local authorities
to preserve health resources and maintain social distancing. Furthermore, ESHRE and other societies recommended to postpone ART
pregnancies as of 14 March 2020.
STUDY DESIGN, SIZE, DURATION: A structured questionnaire was distributed in April among the ESHRE Committee of National
Representatives, followed by further information collection through email.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The information was collected through the questionnaire and afterwards
summarised and aligned with data from the European Centre for Disease Control on the number of COVID-19 cases per country.
MAIN RESULTS AND THE ROLE OF CHANCE: By aligning the data for each country with respective epidemiological data, we show
a large variation in the time and the phase in the epidemic in the curve when MAR/ART treatments were suspended and restarted.
Similarly, the duration of interruption varied. Fertility preservation treatments and patient supportive care for patients remained available
during the pandemic.
LARGE SCALE DATA:N/A
LIMITATIONS, REASONS FOR CAUTION: Data collection was prone to misinterpretation of the questions and replies, and required
further follow-up to check the accuracy. Some representatives reported that they, themselves, were not always aware of the situation
throughout the country or reported difficulties with providing single generalised replies, for instance when there were regional differences
within their country.
WIDER IMPLICATIONS OF THE FINDINGS: The current article provides a basis for further research of the different strategies
developed in response to the COVID-19 crisis. Such conclusions will be invaluable for health authorities and healthcare professionals with
respect to future similar situations.
ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committees of ESHRE.
VC The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
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Introduction
After the local outbreak of coronavirus disease 2019 (COVID-19) in
Wuhan (China) in December 2019, it did not take long before the
virus reached Europe and then the rest of the world. The first cases
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in Europe were reported in France on the 24th of January
2020 and in Germany on the 28th of January 2020 (Fig. 1). On the
30th of January 2020, the World Health Organization (WHO) de-
clared this first outbreak of novel coronavirus a ‘public health emer-
gency of international concern’ (World Health Organization,
2020a). By the end of February, the Italian authorities reported clus-
ters of cases in Lombardy and additional cases in two other regions,
Piedmont and Veneto. Public health measures were installed shortly
thereafter. On the 11th of March 2020, the Director-General of the
WHO declared COVID-19 a global pandemic (World Health
Organization, 2020b). As of 25th of March 2020, cases have been
reported in all European Union/European Economic Area countries
(European Centre for Disease Prevention and Control, 2020), with
Montenegro as the last European country to report SARS-CoV-2
positive patients.
In response to the outbreak of the virus in Europe, ESHRE
launched, on the 27th of February 2020, a first statement advising a
precautionary approach and recommending avoiding ART pregnan-
cies in patients who meet the diagnostic criteria for COVID-19. In
mid-March, ESHRE recommended expanding this advice to all
patients even if they did not meet the COVID-19 diagnostic criteria.
A more elaborated statement was published in early April 2020,
advising not to start new ART for the following reasons: to avoid
complications from ART and ART-pregnancy; to avoid potential
SARS-CoV-2-related complications during pregnancy; to mitigate
the unknown risk of vertical transmission in SARS-CoV-2 positive
patients; to support the necessary re-allocation of healthcare
resources; and to observe the current recommendations of social
distancing. This statement also included an exception for urgent fer-
tility preservation treatments, stating that cryopreservation of game-
tes, embryos and germinal tissue should still be considered, being an
emergency procedure for patients that otherwise could potentially
become sterile. In addition, ESHRE took the initiative to measure
the impact of COVID-19 pandemic on the practice of medically as-
sisted reproduction (MAR)/ART across Europe by using a purposely
devised questionnaire.
Materials and methods
An eight-question survey (Supplementary Data) was distributed among
the members of the ESHRE Committee of National Representatives
(CNR) on the 7th of April 2020. The national representatives were
asked about the status of ART activity in their respective countries at
that time. They were also asked to detail the treatments being per-
formed, and the ones temporarily stopped. After the initial survey, the
CNR was approached to give a regular update on the activity status in
their country. If treatments restarted, they were asked for more
details on restrictions or precautions. Data were analysed and pre-
sented in a table and visual format, published on the ESHRE site at the
time of creation and in a time progressive manner (www.eshre.eu/cov
idwg). Discrepant or unclear data were clarified with the CNR through
email, and the same country representatives were asked to confirm
that the overview of information on their country (Supplementary
Table SI) was correct.
To investigate any factors that could be linked to both the date of
stopping treatments, the date of the restart of treatments and the du-
ration of activity cessation, we included national data on daily reported
COVID-19 cases and deaths, available from the European Centre for
Disease Control (https://www.ecdc.europa.eu/en/publications-data/
download-todays-data-geographic-distribution-covid-19-cases-world
wide). The dates of stop and restart of MAR/ART treatments were
added to the curves and alignment with different phases in the
curves was assessed.
Furthermore, we investigated the possible correlation between
the duration of the MAR/ART treatment cessation and the
reported COVID-19 cases per 100 000 population: the latter was
calculated from the national data from the European Centre for
Disease Control.
WHAT DOES THIS MEAN FOR PATIENTS?
The coronavirus disease 2019 (COVID-19) pandemic had a large impact on infertile couples. Fertility clinics closed their doors or reduced
their services either voluntarily or after a recommendation from national authorities. This article provides an overview of how and when
COVID-19 impacted on access to fertility services within Europe, aiming to provide a basis for further research, for instance on the
effects of stopping treatment on infertile couples. The data in this article combined with additional research will help fertility clinics and
authorities to manage the care for infertile couples in a future global pandemic.















































Information was collected from 41 out of 51 European countries, and
all results below are based on data from the 41 European countries
unless otherwise specified.
Timeline of MAR/ART treatments stop/
restart
Collected data from the survey on MAR/ART activity allowed the
construction of a timeline. An overview of discontinuation and restart
of MAR/ART activities in Europe at 2-week intervals between the 1st
of March and the 29th of May 2020 is represented in Fig. 2. Italy was
the first country where MAR/ART activity was halted, as of the 1st of
March 2020. By the 15th of March, nine countries had stopped all
ART activity, and in four additional countries, some centres had
stopped their activity. By the 1st of April, all countries for which data
are available reported a halt (complete or partial) of MAR/ART activ-
ity. For some countries (Norway, Sweden), the representatives
reported only a minimal impact of the COVID-19 pandemic on MAR/
ART activity, limited to public centres that reduced activities mainly
due to the re-allocation of health resources or staff.
The first countries to restart activities were the Czech Republic,
Denmark, Germany, Luxemburg and Norway, during the week of the
20th of April 2020. Most of the remaining countries awaited the begin-
ning of May to restart MAR/ART activity. These data focused on
MAR/ART treatments being performed, excluding fertility preservation
treatments (see below) and online or telephone patient consultations,
before reopening. In most countries, online and telephone patient sup-
port were available during the period when MAR/ART centres were
closed.
In 57.5% (n¼ 23) of 40 countries for which the information was
available, stopping ART activities was recommended by local or na-
tional authorities and in 27.5% (n¼ 11) of countries stopping was
enforced by the local authorities. Six representatives reported that
clinics stopped their activities voluntarily in their country and some in-
dicated that this was based on international recommendations such as
the ESHRE statement (Fig. 3).
Public versus private ART centres
In most European countries, ART is performed in private and public
centres. Representatives were asked to indicate whether there was
a difference in MAR/ART activity with regards to the status of pub-
lic or private services in the period of treatment suspension.
Analysis excluded countries in which there are either only private or
only public ART centres (n¼ 5) or for which the information was
not available (n¼ 7). Of the remaining 29 countries, 18 (62.1%)
reported that there was no difference between public or private
centres, 11 (37.9%) reported that there was less impact on the pri-
vate centres, stating that either fewer private centres were closed
or that activity in the private centres was not interrupted. None of
the country representatives reported more activity in the public
centres compared to the private centres. Although the question
Figure 1 Timeline for the outbreak of COVID-19 in Europe. COVID-19, coronavirus disease 2019; MAR, medically assisted reproduction;
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; EU/EAA, European Union/European Economic Area; WHO, World Health
Organization.
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Figure 2 Overview of cessation and restart of MAR/ART activities in Europe between 1st of March and 30th of May 2020.
Figure 3 Overview of whether suspension of MAR/ART treatments was voluntary, recommended or enforced by national or
local authorities.



























































was not asked specifically, some countries (Slovakia, Montenegro)
reported a discrepancy in restarting activities, with activity restarting
earlier in private centres.
Urgent fertility preservation treatments
Although not included in the initial survey, several CNR commented
that interventions for urgent fertility preservation were not interrupted.
After further questioning, representatives of 38 countries were able to
provide information on the availability of medical fertility preservation
treatments. In 32 countries (84.2%), treatments for urgent fertility
preservation were performed throughout the entire period and in six
countries (15.7%), ART centres were closed for all patients, including
fertility preservation patients.
Factors related to the date of stop and
restart of activities
To elucidate if the decision to restart ART therapy was based on the
reported number of newly diagnosed COVID-19 cases in a country,
we superimposed the date of ART ‘stop’ and ART ‘restart’ on the
timeline of the number of daily diagnosed COVID-19 cases, as pub-
lished by the European Centre for Disease Control (https://www.
ecdc.europa.eu/en/publications-data/download-todays-data-geographic-
distribution-covid-19-cases-worldwide). It should be noted that the
number of daily COVID-19 cases is dependent on the country reporting
and testing availability and methods, which varied over the duration of
the pandemic.
On the respective charts, the date ART activity was stopped (partial
or complete) and the date of restart is indicated (Fig. 4 and
Supplementary Fig. S1).
From the graphs, it can be concluded that there is a large variation
in the time when MAR/ART treatments were suspended and when
they were restarted. Similarly, a large variation was found in the
number of COVID-19 cases/deaths at the date of stopping MAR/
ART treatments, with a mean number of cumulative COVID-19 cases
of 3568.82 (ranging from 3 to 111 680 cases) and a mean cumulative
number of COVID-19 deaths of 222.03 (ranging from 0 to 8189).
Calculating the cumulative cases per 100 000 population did not re-
duce the variation, with a mean of 16.39 cases per 100 000 (ranging
from 0.01 to 239.02) and 0.50 deaths (ranging from 0 to 17.53) per
100 000 population at the date treatments were stopped.
On average, ART activity was paused for 48.76 days, ranging
from 23 to 92 days, based on data from 37 countries for which the
exact date of stop and start of activity was available. The possible
correlation between the duration of ART activity discontinuation
and the impact of the COVID-19 pandemic on the respective coun-
try was analysed: the latter quantified by the number of reported
COVID-19 cases/deaths per 100 000 inhabitants. No correlation
between the duration of ART activity discontinuation and the im-
pact of the COVID-19 pandemic on the respective country was
detected (Supplementary Fig. S2)
On the graphs of the different countries, we could divide the curves
into four phases of the epidemic, starting with a linear phase (‘lag
phase’), a phase of an exponential increase in the daily reported
COVID-19 cases (‘exponential phase’), a plateau (‘stationary phase’)
and a phase of decrease in the reported cases (‘decline phase’)
(Fig. 5A). For every country, the stage of the curve was estimated for
the day that stop and restart of activity occurred. In most of the coun-
tries (77.5%, 31/40), the MAR/ART activity was stopped during the
exponential phase, mostly at the beginning of the phase. Some coun-
tries (n¼ 6, 15.0%) had already stopped ART at the lag phase, while
others (n¼ 3, 7.5%) postponed any action until the epidemiologic
curve reached the stationary phase. Similarly, for restarting activity,
most countries (n¼ 30; 75.0%) restarted during the early decline
phase, although in 10 (25.0%) countries activity was already restarted
in the stationary phase before the decline phase started (Fig. 5B).
Figure 4 Examples of the reported number of daily new cases and deaths associated with COVID-19, with an indication of the
date MAR/ART activity was stopped (red) and restarted (green) for four countries. Graphs on all countries are included in
Supplementary Figure S1.








































The current article presents a longitudinal overview of the impact of
the COVID-19 pandemic on the provision of ART activities in Europe.
In most European countries, MAR/ART activities were stopped in
March, most often after a recommendation from the local authorities
or national scientific society. As of the second half of April, treatments
resumed gradually in different countries.
In addition to representing the data from different countries, we in-
vestigated possible factors related to the date of stopping and restart-
ing activity. We could not find any specific threshold in the
epidemiologic curve related to the stop or restart of treatment, nor
did we detect a correlation between the number of reported cases
per 100 000 population and the duration the treatments were halted.
From the data and the graphs per country, we could derive that in
most countries MAR/ART activity was stopped when the epidemio-
logic curve hit the exponential phase (i.e. when the daily increase of
COVID-19 patients was exponential), and activities were restarted
when the daily number of new COVID-19 patients declined (decline
phase).
We have no detailed information as to the reasoning behind the
stopping and restarting of MAR/ART activity. ESHRE stated (2nd of
April 2020) that treatments should be suspended for the reasons al-
ready mentioned in the introduction of this article. With regards to
restarting, it can be assumed that activity restarted when the impact of
COVID-19 on healthcare resources was reduced. Also, at that time,
the chance of infection and hence potential SARS-CoV-2-related com-
plications during pregnancy was reduced. In this reasoning, it can be
assumed that the unknown risk of vertical transmission was not a ma-
jor factor in decision-making. Another hypothesis is that treatment halt
and resumption is influenced by international guidance, and by actions
in neighbouring countries. These factors could indeed explain that
apart from Italy, ART activities were stopped as of 14 March, shortly
after the WHO declared ‘COVID-19 a global pandemic’ and after
ESHRE and other international scientific societies recommended to
postpone pregnancies through ART. Similarly, activity restarted mainly
in Week 17 and 18, shortly after ESHRE published its guidance for
recommencing ART treatments. This guidance provided information
on how to reorganise MAR/ART activities to ensure social distancing
requirements are met (The ESHRE COVID-19 Working Group,
2020).
The current report has some limitations with regards to the data,
which were collected on a voluntary basis by the members of the
ESHRE CNR. There was room for interpretation in the questions and
Figure 5 Treatment stop and restart according to the phases in the epidemic. (A) Overview of the different graphs for a single country,
including a division in four phases of the epidemiological curve, including lag, exponential stationary and decline phase. (B) The percentages of coun-
tries that stopped and restarted their activities per phase of the epidemiologic curve.






























































































discrepancy in the initial replies to the survey, which was circumvented
by asking for further details and a confirmation that the information
summarised in the table (Supplementary Table SI) reflected the situa-
tion in the country. Still, some representatives reported that they
themselves were not always aware of the situation throughout the
country. Another limitation was the collection of data at a national
level, while for some larger countries, the recommendations, and
actions were performed at a regional level. As the impact of the
COVID-19 pandemic differed between regions of the same country,
the impact on ART varied similarly. At least for some countries, such
as Italy, France, Russia and Germany, there were regional variations.
The information in this article did not allow the inclusion of such
details for each country, but the dates for stop and restart of activity
in these countries may represent an oversimplification.
Despite the above limitations, the presented impact of a global pan-
demic upon ART activity provides valuable information. First of all, the
cessation of ART activities was of a relatively short duration, about
7 weeks, and it seems that activity was restarted as soon as a decline
in the curve of daily new confirmed cases was established. This could
also be related to the fact that infertility is a WHO recognised disease
and that ART treatment should be considered of major importance.
Furthermore, the significant impact that a cessation of treatments
could have on the psychosocial health of infertile couples was a factor
to be considered. This impact is highlighted in a statement from the
American Society for Reproductive Medicine, ESHRE and the
International Federation of Fertility Societies (Assisted Reproduction
and COVID-19, 2020). A second observation was the significant varia-
tion between European countries, both on the impact of the COVID-
19 crisis and the actions with regards to MAR/ART treatments. The
latter is seen in the variation in the duration of time when activity was
stopped and the phase and number of COVID-19 cases at the dates
of stopping and restarting activity. Finally, documented data such as
those presented in this article will provide a basis for further research
regarding different strategies developed by countries in response to
the COVID-19 crisis, and such conclusions will be valuable for health
authorities and healthcare professionals in case of a future global
pandemic.
This manuscript can act as a blueprint for performing data collection
and assessment of services in the circumstances of a major global
event that has an immediate impact upon daily life and the provision
of medical assistance to all in need.
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